AGC Biologics Partners with BioNTech SE to Further Supply Plasmid DNA Starting Material for the Pfizer-BioNTech COVID-19 vaccine, at AGCs Heidelberg, Germany facility
06/07/2021 | 10:06am EST
AGC Biologics has announced its partnership with BioNTech SE to further supply Plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine, at AGC's Heidelberg, Germany facility. AGC Biologics will manufacture and supply BioNTech with pDNA starting material, an essential component of BioNTech's mRNA-based vaccine manufacturing process. AGC Biologics' Heidelberg facility has over 20 years of experience delivering a very wide range of microbial programs for customers.
In addition, the site is AGC's Center of Excellence for Plasmid DNA (pDNA) production, as part of their end-to-end Cell and Gene Therapy offering.